Anne-Lise Poulat

Anne-Lise Poulat

Auto-generated profile, based on publicly available information

Anne-Lise Poulat

Service de Neurologie Pédiatrique, Groupement Hospitalier Est, Hospices Civils de Lyon, 59, boulevard pinel, Bron 69677, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in European Journal of Paediatric Neurology
Verified
Journal Article
Open access
TYT. Michael Yates
T. Michael Yates
MSMohnish Suri
Mohnish Suri
ADArchana Desurkar
Archana Desurkar
GLGaetan Lesca
Gaetan Lesca
CWCarina Wallgren-Pettersson
Carina Wallgren-Pettersson
Meena BalasubramanianMeena Balasubramanian
Meena Balasubramanian
We aim to further delineate the phenotype associated with pathogenic variants in the SLC35A2 gene, and review all published literature to-date. This gene is located on the X chromosome and encodes a UDP-galactose transporter. Pathogenic variants in SLC35A2 cause a congenital disorder of glycosylation. The condition is rare, and less than twenty patients have been reported to-date. The phenotype is complex and has not been fully defined. Here, we present a series of five patients with de novo pathogenic variants in SLC35A2. The patients' phenotype includes developmental and epileptic encephalopathy with hypsarrhythmia, facial dysmorphism, severe intellectual disability, skeletal abnormalities, congenital cardiac disease and cortical visual impairment. Developmental and epileptic encephalopathy with hypsarrhythmia is present in most patients with SLC35A2 variants, and is drug-resistant in the majority of cases. Adrenocorticotropic hormone therapy may achieve partial or complete remission of seizures, but the effect is usually temporary. Isoelectric focusing of transferrins may be normal after infancy, therefore a congenital disorder of glycosylation should still be considered as a diagnosis in the presence of a suggestive phenotype. We also provide evidence that cortical visual impairment is part of the phenotypic spectrum.

29 January 2022 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
PGPauline Garel
Pauline Garel
GLGaetan Lesca
Gaetan Lesca
DVDorothée Ville
Dorothée Ville
APAnne-Lise Poulat
Anne-Lise Poulat
NCNicolas Chatron
Nicolas Chatron
LLLaurence Lion-François
Laurence Lion-François

1 August 2024 in Neurology Genetics
Verified
Journal Article
Open access
ACAngela Clara-Hwang
Angela Clara-Hwang
SSStefani Stefani
Stefani Stefani
TLTracy Lau
Tracy Lau
MSMarcello Scala
Marcello Scala
BABüşra Aynekin
Büşra Aynekin
Stephanie EfthymiouStephanie Efthymiou
Stephanie Efthymiou
To present a case series of novel CHD2 variants in patients presenting with genetic epileptic and developmental encephalopathy. CHD2 gene encodes an ATP-dependent enzyme, chromodomain helicase DNA-binding protein 2, involved in chromatin remodeling. Pathogenic variants in CHD2 are linked to early-onset conditions such as developmental and epileptic encephalopathy, drug-resistant epilepsies, and neurodevelopmental disorders. Approximately 225 diagnosed patients from 28 countries exhibit various allelic variants in CHD2, including small intragenic deletions/insertions and missense, nonsense, and splice site variants. We present the molecular and clinical characteristics of 17 unreported individuals from 17 families with novel pathogenic or likely pathogenic variants in CHD2. All individuals presented with severe global developmental delay, childhood-onset myoclonic epilepsy, and additional neuropsychiatric features, such as behavioral including autism, ADHD, and hyperactivity. Additional findings include abnormal reflexes, hypotonia and hypertonia, motor impairment, gastrointestinal problems, and kyphoscoliosis. Neuroimaging features included hippocampal signal alterations (4/10), with additional volume loss in 2 cases, inferior vermis hypoplasia (7/10), mild cerebellar atrophy (4/10), and cerebral atrophy (1/10). Our study broadens the geographic scope of CHD2-related phenotypes, providing valuable insights into the prevalence and clinical characteristics of this genetic disorder in previously underrepresented populations.

8 May 2025 in European Journal of Paediatric Neurology
Verified
Journal Article
Open access
CRCaroline Rey
Caroline Rey
LGLaetitia Giorgi
Laetitia Giorgi
HMHélène Maurey
Hélène Maurey
APAnne-Lise Poulat
Anne-Lise Poulat
DADaniel Amsallem
Daniel Amsallem
KDKumaran Deiva
Kumaran Deiva
To identify factors associated with the neurological outcome of HSVE in children. In this retrospective multicentric observational study, clinical, paraclinical data at onset and neurological outcomes at last follow-up of children (≥28 days and <18 years old) with HSVE, were studied. Univariate and multivariate analyses were performed to identify factors associated with neurological outcome. 49 children (mean age of 4.9 ± 5.5 years) were included. At last follow-up of 5.9 ± 3,13 years, 2 children died (4 %) and 37 (76 %) children presented with poor neurological outcome with epilepsy (57 %), intellectual disability (51 %) and language disorders (47 %). Rehabilitation was necessary for 76 % and 59 % had abnormal academic performances. At onset, younger age and seizures were significantly associated to language disorders (p < 0.01), motor disabilities (p = 0.01), and intellectual disabilities (p = 0.01) in univariate analysis. Abnormal MRIs were more frequent in children with neurological sequalae (p = 0.01). Multivariate analyses identified that: (1) epilepsy occurred more frequently in females (p = 0.03), with insular lesions (p = 0.048); (2) language disorders were more common in children who had seizures at onset (p 0.02); (3) motor disorders were more frequent in younger children (p = 0.03) with thalamic lesions (p = 0.04). Our findings indicate that despite decrease in mortality rates, neurological disabilities in children with HSVE still persist at high levels. This underscores the need to enhance HSVE management strategies. Moreover, the identified risk factors associated with poor neurological outcomes can aid in identifying high-risk children, facilitating the implementation of alternative treatment approaches such as immunotherapy or intensive rehabilitation.

23 July 2025 in European Journal of Paediatric Neurology
Verified
Journal Article
Open access
JRJ. Roux
J. Roux
FAF. Angoulvant
F. Angoulvant
MAM. Aubart
M. Aubart
SAS. Auvin
S. Auvin
CBC. Brehin
C. Brehin
KDK. Deiva
K. Deiva
This study aimed to assess neurological manifestations in French children hospitalized with SARS-CoV-2 infection. Secondary objectives were to evaluate the severity of these presentations and estimate the frequency of long-term neurological sequelae. A multicenter observational study was conducted, including 71 children hospitalized for neurological manifestations of SARS-CoV-2 infection from January 2020 to March 2022. The median age was 8.7 years (range 4.2-13), with 49 % being girls. The most common neurological manifestations were encephalitis and meningoencephalitis (32 %). Brain imaging was abnormal in 68 % of cases. Half of the children required admission in intensive care unit (ICU). Nearly one-third of the children had neurological symptoms at the end of the follow-up, with cognitive difficulties being the most reported complaints. No significant associations were made between sex, age, neurological comorbidities, and the severity nor presence of sequelae. However, abnormal brain imaging was significantly associated with a higher risk of ICU stay (OR = 8.01 [95 % CI 2.37-27.1], p < 0.01) and with the presence of sequelae at discharge (OR = 4.65 [1.45-14.9], p = 0.011) and last follow-up (OR = 5.14 [1.40-18.9], p = 0.015). Although rare, neurological manifestations in children with SARS-CoV-2 infection can be severe, with encephalitis as the most common clinical presentation. Abnormal brain imaging is a strong prognostic marker of acute severity and long-term neurological and cognitive sequelae. Objective assessment tools and longer follow-up are necessary to evaluate the long-term outcomes in these children.

23 June 2026 in Neurology
Verified
Journal Article
Closed access
PDF file
FRFlorence Riccardi
Florence Riccardi
BDBeatrice Desnous
Beatrice Desnous
EBEmilie Borloz
Emilie Borloz
ALAnne Lepine
Anne Lepine
CLCaroline Lacoste
Caroline Lacoste
MMMathieu Milh
Mathieu Milh
Background and ObjectivesDevelopmental and epileptic encephalopathies (DEEs) with early burst-suppression EEG (EIDEE-BS) are among the most severe neonatal epileptic syndromes, typically presenting...